Research programme: carnitine analogues - Kensa
Alternative Names: Acyl-carnitine inhibitor - Viral Therapeutics/KensaGroup; Carnitine analogues research programme - Kensa; Carnitine analogues research programme - KensaGroup/Viral Therapeutics; Vagiprev; Z-14Latest Information Update: 16 Jul 2016
At a glance
- Originator Kensa
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Candidiasis; Chronic obstructive pulmonary disease; Mycoses; Nosocomial infections
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Candidiasis in USA
- 16 Jul 2016 No recent reports of development identified for preclinical development in Chronic-obstructive-pulmonary-disease in USA
- 16 Jul 2016 No recent reports of development identified for preclinical development in Mycoses in USA (Topical)